Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China flag China · Delayed Price · Currency is CNY
18.90
-0.30 (-1.56%)
Sep 11, 2026, 3:00 PM CST

Aurisco Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
373.06449.21354.79289.42210.96168.71
Depreciation & Amortization
163.36125.9888.379.1169.2454.77
Other Amortization
2.332.331.92.541.55-
Loss (Gain) From Sale of Assets
0.210.550.411.531.50.4
Asset Writedown & Restructuring Costs
1.310.230.17---
Loss (Gain) From Sale of Investments
-12.71-10.99-5.62-31.721.19-0.68
Provision & Write-off of Bad Debts
7.667.663.554.184.19-0.09
Other Operating Activities
80.7847.8820.463.892.33
Change in Accounts Receivable
-48.92-125.57-107.13-98.18-84.8311.29
Change in Inventory
-139.28-121.19-201.43-72.52-125.97-89.01
Change in Accounts Payable
-13.8342.67161.15174.5570.5655.41
Change in Other Net Operating Assets
0.745.2317.5934.2817.981
Operating Cash Flow
413.89421.5332.41385.61166.41201.57
Operating Cash Flow Growth
8.79%26.80%-13.80%131.72%-17.44%-6.02%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-388.16-350.07-540.28-305.48-216.23-250.61
Sale of Property, Plant & Equipment
1.041.041.280.520.630.6
Divestitures
---61.09--
Investment in Securities
-11.32106.74-191.34-121.44-41.44-15
Other Investing Activities
2.810.113.560.030.252.68
Investing Cash Flow
-395.63-242.19-726.77-365.27-256.79-262.34

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-66986.04135.7937.12-
Total Debt Issued
39.166986.04135.7937.12-
Long-Term Debt Repaid
--68.17-153.64-71.87-5.94-4.37
Lease Payments
-8.17-8.17-6.64-5.55-4.94-4.37
Total Debt Repaid
-89.59-68.17-153.64-71.87-5.94-4.37
Net Debt Issued (Repaid)
-50.49-2.17832.463.9231.18-4.37
Issuance of Common Stock
----57.15-
Repurchase of Common Stock
-55.13-55.13----
Common Dividends Paid
-144.2-124.12-94.82-67-52.34-48.12
Other Financing Activities
50.16--3.2252.1-50.9-
Financing Cash Flow
-199.66-181.42734.3749.02-14.91-52.49

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-36.25-3.5514.026.113.5-3.82
Net Cash Flow
-217.64-5.66354.0275.47-101.79-117.08

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
25.7371.42-207.8780.13-49.82-49.04
Free Cash Flow Growth
------
Free Cash Flow Margin
1.51%4.21%-14.09%6.35%-4.94%-6.11%
Free Cash Flow Per Share
0.060.17-0.520.20-0.12-0.12
Levered Free Cash Flow
-56.71-39.07-309.0336.02-102.36-116.14
Unlevered Free Cash Flow
-35.01-17.38-299.1737.73-101.73-115.74
Free Cash Flow After Leases
17.5763.26-214.5274.58-54.76-53.41

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
27.2517.92-12.74-18.15-35.73-27.6
Change in Working Capital
-202.1-201.33-131.534.55-126.11-23.88